 Christopher Seder
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 32 | 2021 | 756 | 9.210 |
Why?
| | Pneumonectomy | 17 | 2021 | 90 | 5.860 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 14 | 2021 | 374 | 5.420 |
Why?
| | Thoracic Surgery | 13 | 2020 | 33 | 5.000 |
Why?
| | Esophageal Neoplasms | 7 | 2018 | 61 | 3.590 |
Why?
| | Databases, Factual | 13 | 2021 | 391 | 2.700 |
Why?
| | Adenocarcinoma | 8 | 2018 | 237 | 2.390 |
Why?
| | Societies, Medical | 11 | 2020 | 209 | 2.380 |
Why?
| | Thoracic Surgical Procedures | 5 | 2019 | 12 | 2.180 |
Why?
| | Neoplasm Staging | 13 | 2021 | 481 | 2.020 |
Why?
| | Thoracic Wall | 3 | 2016 | 12 | 1.720 |
Why?
| | Quality Improvement | 4 | 2019 | 173 | 1.550 |
Why?
| | Humans | 66 | 2022 | 31481 | 1.440 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 236 | 1.320 |
Why?
| | Postoperative Complications | 6 | 2021 | 1083 | 1.260 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2015 | 40 | 1.190 |
Why?
| | Thoracic Surgery, Video-Assisted | 5 | 2020 | 22 | 1.110 |
Why?
| | Aged | 32 | 2021 | 10295 | 1.070 |
Why?
| | Robotics | 2 | 2013 | 17 | 1.000 |
Why?
| | Female | 39 | 2022 | 18253 | 0.990 |
Why?
| | Colonic Neoplasms | 3 | 2017 | 84 | 0.990 |
Why?
| | Cardiac Surgical Procedures | 2 | 2016 | 98 | 0.980 |
Why?
| | Male | 41 | 2022 | 17583 | 0.960 |
Why?
| | Registries | 2 | 2021 | 214 | 0.880 |
Why?
| | Advisory Committees | 2 | 2018 | 48 | 0.850 |
Why?
| | Lung | 3 | 2021 | 171 | 0.830 |
Why?
| | Checklist | 1 | 2020 | 42 | 0.830 |
Why?
| | Middle Aged | 28 | 2022 | 11209 | 0.820 |
Why?
| | Gases | 1 | 2019 | 6 | 0.800 |
Why?
| | Intubation, Gastrointestinal | 2 | 2010 | 15 | 0.790 |
Why?
| | Hate | 1 | 2019 | 2 | 0.790 |
Why?
| | Chest Tubes | 1 | 2019 | 5 | 0.790 |
Why?
| | Inhibin-beta Subunits | 2 | 2009 | 2 | 0.780 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 456 | 0.780 |
Why?
| | Clostridium Infections | 2 | 2009 | 13 | 0.770 |
Why?
| | Catheter Ablation | 1 | 2020 | 76 | 0.770 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2019 | 207 | 0.760 |
Why?
| | Enteral Nutrition | 2 | 2010 | 64 | 0.760 |
Why?
| | Prognosis | 8 | 2021 | 1028 | 0.730 |
Why?
| | Diaphragm | 1 | 2018 | 7 | 0.720 |
Why?
| | Foreign-Body Migration | 1 | 2018 | 19 | 0.710 |
Why?
| | Mucous Membrane | 1 | 2018 | 42 | 0.710 |
Why?
| | Scoliosis | 1 | 2018 | 35 | 0.690 |
Why?
| | Internationality | 1 | 2017 | 26 | 0.680 |
Why?
| | Aged, 80 and over | 15 | 2018 | 5234 | 0.680 |
Why?
| | Heart Diseases | 2 | 2016 | 102 | 0.680 |
Why?
| | Databases as Topic | 1 | 2017 | 22 | 0.680 |
Why?
| | Benchmarking | 1 | 2017 | 34 | 0.660 |
Why?
| | Quality Assurance, Health Care | 1 | 2017 | 54 | 0.650 |
Why?
| | Prosthesis Failure | 2 | 2018 | 534 | 0.650 |
Why?
| | Risk Assessment | 5 | 2019 | 806 | 0.640 |
Why?
| | Ribs | 1 | 2016 | 19 | 0.630 |
Why?
| | Retrospective Studies | 16 | 2021 | 3591 | 0.620 |
Why?
| | Metformin | 1 | 2016 | 21 | 0.620 |
Why?
| | Pulmonary Blastoma | 1 | 2015 | 4 | 0.620 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 15 | 0.610 |
Why?
| | Testicular Neoplasms | 1 | 2015 | 26 | 0.600 |
Why?
| | Neoplasm Invasiveness | 4 | 2018 | 104 | 0.600 |
Why?
| | Adult | 16 | 2018 | 9779 | 0.600 |
Why?
| | Academic Medical Centers | 1 | 2016 | 158 | 0.600 |
Why?
| | Nurse Practitioners | 1 | 2017 | 119 | 0.590 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2015 | 14 | 0.590 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 76 | 0.590 |
Why?
| | Lung Diseases, Fungal | 1 | 2015 | 10 | 0.590 |
Why?
| | Mucormycosis | 1 | 2015 | 8 | 0.590 |
Why?
| | Cardiology | 1 | 2016 | 102 | 0.590 |
Why?
| | Early Medical Intervention | 1 | 2015 | 18 | 0.580 |
Why?
| | United States | 9 | 2021 | 2539 | 0.550 |
Why?
| | Thoracotomy | 2 | 2016 | 34 | 0.550 |
Why?
| | Quality of Health Care | 1 | 2016 | 141 | 0.550 |
Why?
| | Surgical Mesh | 1 | 2014 | 30 | 0.540 |
Why?
| | Manubrium | 1 | 2014 | 2 | 0.540 |
Why?
| | Risk Adjustment | 3 | 2020 | 14 | 0.540 |
Why?
| | Replantation | 1 | 2014 | 7 | 0.540 |
Why?
| | Clavicle | 1 | 2014 | 16 | 0.540 |
Why?
| | Herniorrhaphy | 1 | 2014 | 36 | 0.540 |
Why?
| | Survival Rate | 7 | 2021 | 465 | 0.530 |
Why?
| | Treatment Outcome | 13 | 2021 | 3910 | 0.530 |
Why?
| | Tricuspid Valve Prolapse | 1 | 2012 | 2 | 0.500 |
Why?
| | Mitral Valve Annuloplasty | 1 | 2012 | 4 | 0.500 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 389 | 0.500 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 224 | 0.500 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 405 | 0.490 |
Why?
| | Prostheses and Implants | 1 | 2014 | 166 | 0.480 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2012 | 49 | 0.470 |
Why?
| | Surgery, Computer-Assisted | 1 | 2012 | 61 | 0.470 |
Why?
| | Breast Neoplasms | 2 | 2017 | 442 | 0.460 |
Why?
| | Spinal Fusion | 1 | 2018 | 464 | 0.440 |
Why?
| | Myxoma | 1 | 2010 | 7 | 0.420 |
Why?
| | Mitral Valve | 1 | 2010 | 17 | 0.420 |
Why?
| | Survival Analysis | 3 | 2018 | 379 | 0.420 |
Why?
| | Heart Neoplasms | 1 | 2010 | 21 | 0.420 |
Why?
| | Neoadjuvant Therapy | 3 | 2022 | 71 | 0.410 |
Why?
| | Tomography, X-Ray Computed | 6 | 2018 | 891 | 0.400 |
Why?
| | Aneurysm, Infected | 1 | 2009 | 1 | 0.390 |
Why?
| | Aortitis | 1 | 2009 | 1 | 0.390 |
Why?
| | Clostridium septicum | 1 | 2009 | 1 | 0.390 |
Why?
| | Energy Intake | 1 | 2010 | 99 | 0.390 |
Why?
| | Blood Component Transfusion | 1 | 2009 | 4 | 0.390 |
Why?
| | Embolism | 1 | 2009 | 5 | 0.390 |
Why?
| | Embolectomy | 1 | 2009 | 6 | 0.390 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2009 | 5 | 0.390 |
Why?
| | Jehovah's Witnesses | 1 | 2009 | 3 | 0.390 |
Why?
| | Treatment Refusal | 1 | 2009 | 13 | 0.390 |
Why?
| | Aortic Aneurysm | 1 | 2009 | 16 | 0.390 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2009 | 16 | 0.390 |
Why?
| | Religion and Medicine | 1 | 2009 | 24 | 0.380 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2009 | 136 | 0.380 |
Why?
| | Ischemia | 1 | 2009 | 35 | 0.380 |
Why?
| | Blood Vessel Prosthesis Implantation | 3 | 2018 | 44 | 0.380 |
Why?
| | Bronchoscopy | 3 | 2019 | 38 | 0.370 |
Why?
| | Internship and Residency | 3 | 2018 | 201 | 0.370 |
Why?
| | Intraoperative Complications | 1 | 2009 | 76 | 0.370 |
Why?
| | Length of Stay | 4 | 2016 | 377 | 0.370 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 95 | 0.360 |
Why?
| | Surgeons | 2 | 2020 | 84 | 0.360 |
Why?
| | Hospital Costs | 1 | 2008 | 73 | 0.350 |
Why?
| | Education, Medical, Graduate | 2 | 2020 | 83 | 0.350 |
Why?
| | Critical Care | 1 | 2010 | 234 | 0.330 |
Why?
| | Sarcoma | 2 | 2021 | 139 | 0.330 |
Why?
| | Disease-Free Survival | 2 | 2017 | 241 | 0.310 |
Why?
| | Intensive Care Units | 1 | 2008 | 316 | 0.310 |
Why?
| | Follow-Up Studies | 5 | 2021 | 2028 | 0.300 |
Why?
| | Clinical Competence | 3 | 2020 | 274 | 0.300 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 68 | 0.280 |
Why?
| | Surgical Flaps | 2 | 2015 | 54 | 0.270 |
Why?
| | Esophagectomy | 2 | 2016 | 25 | 0.270 |
Why?
| | Chemoradiotherapy | 2 | 2015 | 69 | 0.260 |
Why?
| | Bronchi | 2 | 2015 | 19 | 0.250 |
Why?
| | Thymoma | 2 | 2020 | 15 | 0.250 |
Why?
| | Thymus Neoplasms | 2 | 2020 | 14 | 0.250 |
Why?
| | Early Detection of Cancer | 3 | 2019 | 91 | 0.240 |
Why?
| | Intubation, Intratracheal | 2 | 2016 | 70 | 0.240 |
Why?
| | Metastasectomy | 1 | 2021 | 7 | 0.230 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 23 | 0.230 |
Why?
| | Lymph Nodes | 2 | 2020 | 84 | 0.230 |
Why?
| | Multivariate Analysis | 3 | 2017 | 390 | 0.220 |
Why?
| | Cohort Studies | 4 | 2018 | 2014 | 0.220 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 16 | 0.220 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 290 | 0.220 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 31 | 0.210 |
Why?
| | Incidence | 2 | 2021 | 829 | 0.210 |
Why?
| | Mediastinal Cyst | 1 | 2020 | 1 | 0.210 |
Why?
| | Consensus | 1 | 2020 | 106 | 0.200 |
Why?
| | RNA, Messenger | 3 | 2009 | 371 | 0.200 |
Why?
| | Carcinoma | 2 | 2017 | 84 | 0.190 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 13 | 0.190 |
Why?
| | Risk Factors | 3 | 2019 | 2664 | 0.190 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 73 | 0.190 |
Why?
| | False Positive Reactions | 1 | 2019 | 40 | 0.190 |
Why?
| | Smoking | 1 | 2020 | 202 | 0.190 |
Why?
| | Computer Simulation | 1 | 2020 | 249 | 0.190 |
Why?
| | Drainage | 1 | 2019 | 55 | 0.190 |
Why?
| | RNA, Small Interfering | 2 | 2009 | 72 | 0.190 |
Why?
| | Unnecessary Procedures | 1 | 2019 | 30 | 0.190 |
Why?
| | Thoracoscopy | 3 | 2019 | 20 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 580 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 2 | 2009 | 230 | 0.180 |
Why?
| | Hemoptysis | 1 | 2018 | 9 | 0.180 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2018 | 18 | 0.180 |
Why?
| | HLA Antigens | 1 | 2018 | 20 | 0.180 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2018 | 9 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2018 | 17 | 0.180 |
Why?
| | Laparoscopy | 2 | 2011 | 190 | 0.180 |
Why?
| | Syndecan-1 | 1 | 2018 | 10 | 0.180 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 21 | 0.180 |
Why?
| | Aneurysm, Dissecting | 1 | 2018 | 21 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 375 | 0.180 |
Why?
| | Radiography, Thoracic | 1 | 2018 | 39 | 0.180 |
Why?
| | Chest Pain | 1 | 2018 | 23 | 0.180 |
Why?
| | Cell Proliferation | 2 | 2009 | 232 | 0.180 |
Why?
| | Morbidity | 2 | 2019 | 71 | 0.180 |
Why?
| | Immunoassay | 1 | 2018 | 45 | 0.180 |
Why?
| | Tobacco | 1 | 2017 | 7 | 0.180 |
Why?
| | Immunohistochemistry | 2 | 2009 | 494 | 0.170 |
Why?
| | Tracheomalacia | 1 | 2017 | 5 | 0.170 |
Why?
| | Tracheal Stenosis | 1 | 2017 | 8 | 0.170 |
Why?
| | Nerve Growth Factors | 1 | 2018 | 46 | 0.170 |
Why?
| | Heart Failure | 1 | 2021 | 232 | 0.170 |
Why?
| | Silicones | 1 | 2017 | 14 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 467 | 0.170 |
Why?
| | Bronchial Neoplasms | 1 | 2017 | 14 | 0.170 |
Why?
| | Airway Obstruction | 1 | 2017 | 21 | 0.170 |
Why?
| | Suture Techniques | 1 | 2018 | 138 | 0.170 |
Why?
| | Lymphoma | 1 | 2017 | 56 | 0.160 |
Why?
| | History, 21st Century | 1 | 2016 | 39 | 0.160 |
Why?
| | History, 19th Century | 1 | 2016 | 77 | 0.160 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 41 | 0.160 |
Why?
| | Melanoma | 1 | 2017 | 63 | 0.160 |
Why?
| | History, 20th Century | 1 | 2016 | 94 | 0.160 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2016 | 10 | 0.160 |
Why?
| | Pneumonia, Bacterial | 1 | 2016 | 15 | 0.160 |
Why?
| | Biopsy | 1 | 2017 | 283 | 0.160 |
Why?
| | Europe | 1 | 2016 | 88 | 0.160 |
Why?
| | Tracheostomy | 1 | 2016 | 28 | 0.150 |
Why?
| | Ifosfamide | 1 | 2015 | 16 | 0.150 |
Why?
| | Etoposide | 1 | 2015 | 64 | 0.150 |
Why?
| | Stents | 1 | 2017 | 155 | 0.150 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2010 | 300 | 0.150 |
Why?
| | Mass Screening | 1 | 2017 | 199 | 0.150 |
Why?
| | Models, Statistical | 1 | 2016 | 144 | 0.150 |
Why?
| | Prospective Studies | 1 | 2021 | 1934 | 0.150 |
Why?
| | Cisplatin | 1 | 2015 | 107 | 0.150 |
Why?
| | Thymus Gland | 1 | 2015 | 28 | 0.150 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 390 | 0.140 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 15 | 0.140 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 150 | 0.140 |
Why?
| | Thoracic Cavity | 1 | 2014 | 1 | 0.140 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2014 | 60 | 0.140 |
Why?
| | Thoracic Neoplasms | 1 | 2014 | 10 | 0.140 |
Why?
| | Time Factors | 1 | 2019 | 1902 | 0.130 |
Why?
| | Comorbidity | 1 | 2016 | 562 | 0.130 |
Why?
| | Mediastinum | 1 | 2013 | 8 | 0.130 |
Why?
| | Hernia, Hiatal | 1 | 2013 | 14 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 274 | 0.130 |
Why?
| | Chicago | 1 | 2016 | 955 | 0.130 |
Why?
| | Fatal Outcome | 2 | 2011 | 75 | 0.120 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2012 | 7 | 0.120 |
Why?
| | Histone Acetyltransferases | 2 | 2009 | 3 | 0.120 |
Why?
| | Histone Deacetylases | 2 | 2009 | 12 | 0.120 |
Why?
| | Acetylation | 2 | 2009 | 15 | 0.120 |
Why?
| | Dyspnea | 1 | 2012 | 35 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 74 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 191 | 0.120 |
Why?
| | Gastric Fistula | 1 | 2011 | 4 | 0.110 |
Why?
| | Fistula | 1 | 2011 | 6 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2011 | 11 | 0.110 |
Why?
| | Anastomotic Leak | 1 | 2011 | 9 | 0.110 |
Why?
| | Living Donors | 1 | 2011 | 16 | 0.110 |
Why?
| | Reconstructive Surgical Procedures | 1 | 2014 | 226 | 0.110 |
Why?
| | Age Factors | 2 | 2016 | 943 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2011 | 37 | 0.110 |
Why?
| | Endoleak | 1 | 2010 | 1 | 0.110 |
Why?
| | Postoperative Hemorrhage | 1 | 2011 | 31 | 0.110 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2011 | 32 | 0.110 |
Why?
| | Sutures | 1 | 2011 | 44 | 0.110 |
Why?
| | Chordae Tendineae | 1 | 2010 | 1 | 0.110 |
Why?
| | Graft Rejection | 1 | 2011 | 84 | 0.110 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 22 | 0.110 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2010 | 13 | 0.110 |
Why?
| | Surgical Tape | 1 | 2010 | 3 | 0.100 |
Why?
| | Blood Vessel Prosthesis | 1 | 2010 | 27 | 0.100 |
Why?
| | Conscious Sedation | 1 | 2010 | 6 | 0.100 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 18 | 0.100 |
Why?
| | APACHE | 1 | 2010 | 32 | 0.100 |
Why?
| | Monitoring, Intraoperative | 1 | 2010 | 43 | 0.100 |
Why?
| | Equipment Failure | 1 | 2010 | 50 | 0.100 |
Why?
| | Trachea | 1 | 2010 | 23 | 0.100 |
Why?
| | Gastric Bypass | 1 | 2011 | 56 | 0.100 |
Why?
| | Endovascular Procedures | 1 | 2010 | 79 | 0.100 |
Why?
| | Activins | 1 | 2009 | 1 | 0.100 |
Why?
| | Follistatin | 1 | 2009 | 1 | 0.100 |
Why?
| | Tissue Array Analysis | 1 | 2009 | 6 | 0.100 |
Why?
| | Mesenteric Artery, Superior | 1 | 2009 | 5 | 0.100 |
Why?
| | Iliac Artery | 1 | 2009 | 8 | 0.100 |
Why?
| | Probability | 1 | 2009 | 104 | 0.100 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 23 | 0.100 |
Why?
| | Digestive System Surgical Procedures | 1 | 2009 | 27 | 0.100 |
Why?
| | Histones | 1 | 2009 | 32 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 156 | 0.100 |
Why?
| | Aorta | 1 | 2009 | 31 | 0.100 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2008 | 8 | 0.090 |
Why?
| | Transfection | 1 | 2009 | 154 | 0.090 |
Why?
| | Blood Pressure | 1 | 2010 | 260 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 108 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2010 | 218 | 0.090 |
Why?
| | Safety | 1 | 2008 | 59 | 0.090 |
Why?
| | Debridement | 1 | 2009 | 99 | 0.090 |
Why?
| | Cattle | 1 | 2009 | 260 | 0.090 |
Why?
| | Blotting, Western | 1 | 2009 | 225 | 0.090 |
Why?
| | Glycoproteins | 1 | 2008 | 65 | 0.090 |
Why?
| | Cost-Benefit Analysis | 1 | 2008 | 153 | 0.090 |
Why?
| | Acute Disease | 1 | 2009 | 254 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 160 | 0.090 |
Why?
| | Recurrence | 1 | 2009 | 389 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2008 | 129 | 0.090 |
Why?
| | Autoantibodies | 1 | 2008 | 119 | 0.090 |
Why?
| | Up-Regulation | 1 | 2009 | 220 | 0.090 |
Why?
| | Anticoagulants | 1 | 2009 | 151 | 0.080 |
Why?
| | DNA Methylation | 1 | 2009 | 168 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 412 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 1273 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2019 | 886 | 0.070 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 16 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 637 | 0.050 |
Why?
| | Equipment Design | 2 | 2011 | 198 | 0.050 |
Why?
| | Mediastinoscopy | 1 | 2019 | 5 | 0.050 |
Why?
| | Animals | 1 | 2009 | 5312 | 0.050 |
Why?
| | Hemolysis | 1 | 2018 | 11 | 0.050 |
Why?
| | North America | 1 | 2018 | 44 | 0.050 |
Why?
| | Young Adult | 2 | 2017 | 2277 | 0.050 |
Why?
| | Canada | 1 | 2018 | 57 | 0.050 |
Why?
| | Pneumonia | 1 | 2019 | 74 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 51 | 0.050 |
Why?
| | Carcinoma, Embryonal | 1 | 2017 | 3 | 0.040 |
Why?
| | Tonsillar Neoplasms | 1 | 2017 | 3 | 0.040 |
Why?
| | Dilatation | 1 | 2017 | 13 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 2017 | 21 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2017 | 46 | 0.040 |
Why?
| | Propensity Score | 1 | 2016 | 54 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 78 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2017 | 85 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2015 | 10 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2015 | 37 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 21 | 0.040 |
Why?
| | Minnesota | 1 | 2014 | 12 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2015 | 149 | 0.040 |
Why?
| | Postoperative Period | 1 | 2016 | 295 | 0.040 |
Why?
| | Area Under Curve | 1 | 2014 | 79 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 153 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 364 | 0.030 |
Why?
| | Sex Factors | 1 | 2016 | 542 | 0.030 |
Why?
| | Illinois | 1 | 2014 | 266 | 0.030 |
Why?
| | Patient Readmission | 1 | 2015 | 129 | 0.030 |
Why?
| | Cytokines | 1 | 2014 | 364 | 0.030 |
Why?
| | Hematemesis | 1 | 2011 | 2 | 0.030 |
Why?
| | Stomach Ulcer | 1 | 2011 | 5 | 0.030 |
Why?
| | Algorithms | 1 | 2014 | 412 | 0.030 |
Why?
| | Proton Pump Inhibitors | 1 | 2011 | 15 | 0.030 |
Why?
| | Esophageal Perforation | 1 | 2011 | 10 | 0.030 |
Why?
| | Candidiasis | 1 | 2011 | 23 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2011 | 29 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2011 | 7 | 0.030 |
Why?
| | Surgical Stapling | 1 | 2011 | 9 | 0.030 |
Why?
| | Disease Progression | 1 | 2014 | 861 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 39 | 0.030 |
Why?
| | Transducers, Pressure | 1 | 2010 | 5 | 0.030 |
Why?
| | Aortography | 1 | 2010 | 14 | 0.030 |
Why?
| | Graft Survival | 1 | 2011 | 111 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2011 | 116 | 0.030 |
Why?
| | Rupture | 1 | 2010 | 115 | 0.030 |
Why?
| | Obesity, Morbid | 1 | 2011 | 82 | 0.020 |
Why?
| | Hydroxamic Acids | 1 | 2008 | 5 | 0.020 |
Why?
| | Adipokines | 1 | 2008 | 8 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 54 | 0.020 |
Why?
| | Azacitidine | 1 | 2008 | 14 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2008 | 155 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 183 | 0.020 |
Why?
| | Reoperation | 1 | 2011 | 938 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2008 | 687 | 0.020 |
Why?
|
|
Seder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|